Physician profile
Nicholas Argento
NPI 1093781155
$1,055,808.80
in general payments reported to CMS, 2019-2025
50 companies · $129K in 2025
The $129K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158K · 2020: $141K · 2021: $141K · 2022: $206K · 2023: $156K · 2024: $126K · 2025: $129K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $189K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $139K · Travel and Lodging: $47K · Consulting Fee: $22K · Food and Beverage: $13K · Education: $73.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $189,397.12 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $139,429.20 |
| Travel and Lodging | $46,883.86 |
| Consulting Fee | $22,067.00 |
| Food and Beverage | $12,789.17 |
| Education | $73.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $385,716.19 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lilly USA, LLC | $322,495.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $146,470.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47,791.56 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $33,792.34 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $28,372.31 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $25,021.52 | 2019-2025 | Afrezza |
| Eli Lilly and Company | $19,683.98 | 2023-2025 | |
| Insulet Corporation | $16,181.85 | 2019-2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $14,982.76 | 2019 | |
| Convatec INC. | $8,320.00 | 2019-2023 | |
| Ascensia Diabetes Care US INC. | $1,547.66 | 2021-2023 | |
| Zealand Pharma US, INC. | $814.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $754.90 | 2022-2025 | |
| Senseonics, Incorporated | $450.00 | 2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $323.15 | 2019-2025 | Repatha, Repatha, Tepezza |
| Abbott Laboratories | $313.53 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $304.36 | 2021-2025 | |
| Abbvie INC. | $291.09 | 2019-2025 | Synthroid |
| Beta Bionics, INC. | $288.83 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Corcept Therapeutics | $271.92 | 2022-2025 | Korlym |
| Antares Pharma, INC. | $218.80 | 2019-2025 | Xyosted |
| Radius Health, INC. | $174.39 | 2019-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $164.74 | 2022-2025 | Strensiq |
| Sequel Med Tech, LLC | $136.49 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $110.00 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $75.63 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $63.60 | 2024-2025 | Unithroid |
| Madrigal Pharmaceuticals | $60.92 | 2025 | Rezdiffra |
| Medtronic, INC. | $51.76 | 2024 | Minimed 780g |
| Cequr Corporation | $44.89 | 2023-2025 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $43.78 | 2024-2025 | |
| Globus Medical, INC. | $42.80 | 2025 | Senza |
| Amarin Pharma, INC. | $41.17 | 2019-2020 | |
| Kyowa Kirin, INC. | $40.57 | 2024-2025 | Crysvita |
| Recordati_rare_diseases_inc. | $39.21 | 2025 | Isturisa |
| Horizon Therapeutics Plc | $36.21 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $33.17 | 2019 | |
| Tolmar, INC. | $29.00 | 2024-2025 | Jatenzo |
| Chiesi USA, INC. | $28.05 | 2024 | Myalept |
| Almatica Pharma LLC | $24.79 | 2025 | Teriparatide |
| Esperion Therapeutics, INC. | $23.96 | 2025 | Nexletol |
| Ibsa Pharma INC. | $21.74 | 2023 | Tirosint, Licart |
| Lifescan, INC. | $21.34 | 2022 | |
| Grt US Holding, INC. | $18.60 | 2022 | |
| Halozyme INC | $18.03 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $17.51 | 2024 | |
| Acella Pharmaceuticals, LLC | $14.29 | 2025 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $13.24 | 2024 | Contrave |
| Companion Medical, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Argento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.